CTI.L Regulatory News (CTI)

Cathay International Holdings Limited

("Cathay" or the "Company")

Retirement of an Executive Director, the Chief Executive Officer and change in composition of the Executive Committee

Hong Kong, 31 October 2019 - Cathay International Holdings Limited (LSE: CTI.L), today announces that Mr. Lee Jin Yi will retire upon the expiry of his service contract on 24 January 2020. By mutual agreement with the Board, Mr. Lee will cease to be the Chief Executive Officer, Director and member of Executive Committee of the Company with effect from today.

Mr. Lee, aged 62, was appointed as a Director and Chief Executive Officer in 2010. The Chairman and the Board express their sincere gratitude to Mr. Lee for his personal commitment, dedication and the significant contribution made to the Company.

Mr. Lee has confirmed that he is retiring for personal reasons and has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the shareholders of the Company.

Cathay's subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), today also announced that Mr. Lee resigned as a Non-executive Director of Lansen and will cease to be the member of the Remuneration Committee, the member of the Audit Committee and Vice Chairman of the Executive Committee of Lansen today.

- ENDS -

For further enquiries, please contact:

About Cathay 

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.